OBJECTIVE: Chronic Hepatitis C (CHC) is a substantial global public health issue with significant variation between countries be-cause of the genotypic differences. A sustained viral response (SVR) is essential to reduce the complications associated with CHC and can be achieved in most patients via direct-acting an-tivirals (DAAs). The present study aimed at de-termining the genotype distribution in patients with CHC in our region and the SVR in DAA ther-apy patients. PATIENTS AND METHODS: The study was conducted retrospectively on 272 patients treat-ed with DAA between September 2016 and 2021. Data including demographic and clinical char-acteristics of the patients (HCV RNA level, gen-otype, hepatitis B and HIV serology, cirrhosis and decompensation, presence of hepatocellu-lar cancer, degree of hepatosteatosis, previous anti-HCV treatment experience, comorbidities) were recorded. The study's primary endpoint was to determine the SVR at week 24. RESULTS: Genotype 1 was the most common genotype (94.5%), with genotype 1b accounting for most patients (78%) among those. It was ob-served that the patients received Ombitasvir/ Paritaprevir/Ritonavir/Dasabuvir (OPRD) (47%), Ledipasvir/sofosbuvir (LDS) (38%), and Gleca-previr/pibrentasvir (GCP) (15%) as DAA treat-ment. SVR was observed in 92% (223) of the 240 patients at the end of 24 weeks. SVR-24 was sig-nificantly higher in the patient group with serum HCV RNA level s 852.533 (p=0.002), in the hyper-tensive group (p=0.018), and without the psychi-atric disease group (p < 0.001). CONCLUSIONS: A high rate of SVR-24 was achieved by DAAs in CHC patients, most of whom were genotype 1 in the Western Black Sea Region, Turkey. Also, high viral load, hyperten-sion, and psychiatric disease affected SVR-24, and clinical factors, such as cirrhosis, cirrhosis complications, hepatosteatosis, and other co -morbidities did not.